NovoCure (NVCR) EBITDA (2014 - 2026)

NovoCure has disclosed EBITDA across 13 years of filings, most recently posting -$67.4 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$67.4 million, down 78.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$183.4 million (down 9.9% YoY), and the FY2025 annual result was -$153.8 million, up 9.79% from the prior year.
• EBITDA came in at -$67.4 million for Q1 2026 at NovoCure, down from -$40.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$806000.0 in Q1 2022 to a low of -$67.4 million in Q1 2026.
• The 5-year median for EBITDA is -$40.4 million (2025), against an average of -$42.0 million.
• Across the five-year window, EBITDA sank 7375.06% in 2023 and soared 46.41% in 2024, its largest moves.
• NovoCure's EBITDA stood at -$43.0 million in 2022, then slipped by 20.33% to -$51.7 million in 2023, then slipped by 22.41% to -$63.3 million in 2024, then soared by 36.19% to -$40.4 million in 2025, then tumbled by 66.91% to -$67.4 million in 2026.
• The last three EBITDA figures came in at -$67.4 million (Q1 2026), -$40.4 million (Q4 2025), and -$36.0 million (Q3 2025), per Business Quant data.